Advertisement
Advertisement
RNTX
Rein Therapeutics, Inc. Common Stock
0.79
USDSponsored
-0.03
-3.49%
Aug 10, 09:31 UTC -4
Open
RNTX Earnings Reports
Positive Surprise Ratio
RNTX beat 15 of 34 last estimates.
44%
Next Report
In 2 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.17
Implied change from Q1 26 (Revenue/ EPS)
--
/-10.53%
Implied change from Q2 25 (Revenue/ EPS)
--
/-39.29%
Rein Therapeutics, Inc. Common Stock earnings per share and revenue
On May 15, 2026, RNTX reported earnings of -0.19 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 61.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.08% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an decrease of -10.53% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Corvus Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-17.36%
Cullinan Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.82
Actual
-$0.81
Surprise
+1.94%
Oculis Holding AG Ordinary shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.16
Surprise
+60.51%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
MAIA Biotechnology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-15.86%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Zai Lab Limited - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.46
Surprise
-599.09%
FAQ
What were Rein Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Rein Therapeutics, Inc. Common Stock reported EPS of -$0.19, beating estimates by 61.98%, and revenue of $0.00, 0% as expectations.
How did the market react to Rein Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -7.08%, changed from $1.13 before the earnings release to $1.05 the day after.
When is Rein Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Rein Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Rein Therapeutics, Inc. Common Stock is expected to report EPS of -$0.17 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement